CN110613628B - Anti-aging composition, freeze-dried powder containing anti-aging composition and preparation method of freeze-dried powder - Google Patents
Anti-aging composition, freeze-dried powder containing anti-aging composition and preparation method of freeze-dried powder Download PDFInfo
- Publication number
- CN110613628B CN110613628B CN201910837576.6A CN201910837576A CN110613628B CN 110613628 B CN110613628 B CN 110613628B CN 201910837576 A CN201910837576 A CN 201910837576A CN 110613628 B CN110613628 B CN 110613628B
- Authority
- CN
- China
- Prior art keywords
- parts
- freeze
- aging
- dried powder
- oligopeptide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 230000003712 anti-aging effect Effects 0.000 title claims abstract description 47
- 239000000843 powder Substances 0.000 title claims abstract description 34
- 238000002360 preparation method Methods 0.000 title claims abstract description 22
- 239000000203 mixture Substances 0.000 title abstract description 33
- 102000015636 Oligopeptides Human genes 0.000 claims abstract description 33
- 108010038807 Oligopeptides Proteins 0.000 claims abstract description 33
- 102000007562 Serum Albumin Human genes 0.000 claims abstract description 23
- 108010071390 Serum Albumin Proteins 0.000 claims abstract description 23
- 239000003381 stabilizer Substances 0.000 claims description 29
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 27
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 24
- 229930195725 Mannitol Natural products 0.000 claims description 24
- 239000000594 mannitol Substances 0.000 claims description 24
- 235000010355 mannitol Nutrition 0.000 claims description 24
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 claims description 19
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 claims description 19
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 claims description 19
- 239000008367 deionised water Substances 0.000 claims description 18
- 229910021641 deionized water Inorganic materials 0.000 claims description 18
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims description 16
- 239000004471 Glycine Substances 0.000 claims description 8
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 claims description 8
- 235000019799 monosodium phosphate Nutrition 0.000 claims description 8
- 229910000403 monosodium phosphate Inorganic materials 0.000 claims description 8
- AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 claims description 8
- 238000007710 freezing Methods 0.000 claims description 7
- 230000008014 freezing Effects 0.000 claims description 7
- 238000001035 drying Methods 0.000 claims description 6
- 238000001914 filtration Methods 0.000 claims description 6
- 238000010438 heat treatment Methods 0.000 claims description 6
- 238000002156 mixing Methods 0.000 claims description 6
- 230000001954 sterilising effect Effects 0.000 claims description 6
- 238000000859 sublimation Methods 0.000 claims description 6
- 230000008022 sublimation Effects 0.000 claims description 6
- 238000009777 vacuum freeze-drying Methods 0.000 claims description 6
- 229920001213 Polysorbate 20 Polymers 0.000 claims description 4
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 claims description 4
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 claims description 4
- 229940068977 polysorbate 20 Drugs 0.000 claims description 4
- 238000004659 sterilization and disinfection Methods 0.000 claims description 3
- 238000012360 testing method Methods 0.000 abstract description 15
- 230000003020 moisturizing effect Effects 0.000 abstract description 5
- 239000002537 cosmetic Substances 0.000 abstract description 4
- 206010003694 Atrophy Diseases 0.000 abstract description 3
- 230000037444 atrophy Effects 0.000 abstract description 3
- 239000003755 preservative agent Substances 0.000 abstract description 3
- 230000002335 preservative effect Effects 0.000 abstract description 3
- 238000000926 separation method Methods 0.000 abstract description 3
- 238000003860 storage Methods 0.000 abstract description 3
- 230000032798 delamination Effects 0.000 abstract description 2
- 239000008176 lyophilized powder Substances 0.000 description 32
- 230000000052 comparative effect Effects 0.000 description 27
- 210000004027 cell Anatomy 0.000 description 11
- 230000000694 effects Effects 0.000 description 8
- 238000004519 manufacturing process Methods 0.000 description 7
- 238000000034 method Methods 0.000 description 5
- 238000012986 modification Methods 0.000 description 5
- 230000004048 modification Effects 0.000 description 5
- 229930182555 Penicillin Natural products 0.000 description 4
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 4
- 238000011161 development Methods 0.000 description 4
- 230000018109 developmental process Effects 0.000 description 4
- 238000004806 packaging method and process Methods 0.000 description 4
- 229940049954 penicillin Drugs 0.000 description 4
- 239000002504 physiological saline solution Substances 0.000 description 4
- 238000007789 sealing Methods 0.000 description 4
- 239000006285 cell suspension Substances 0.000 description 3
- 239000002994 raw material Substances 0.000 description 3
- 230000036548 skin texture Effects 0.000 description 3
- 238000010998 test method Methods 0.000 description 3
- 238000005303 weighing Methods 0.000 description 3
- 230000003796 beauty Effects 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 238000012258 culturing Methods 0.000 description 2
- 238000005034 decoration Methods 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003995 emulsifying agent Substances 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 238000004108 freeze drying Methods 0.000 description 2
- 238000007747 plating Methods 0.000 description 2
- 238000003825 pressing Methods 0.000 description 2
- 210000000130 stem cell Anatomy 0.000 description 2
- 230000037303 wrinkles Effects 0.000 description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 229920001214 Polysorbate 60 Polymers 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 238000003915 air pollution Methods 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000001153 anti-wrinkle effect Effects 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 230000019771 cognition Effects 0.000 description 1
- 208000010877 cognitive disease Diseases 0.000 description 1
- 238000005336 cracking Methods 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 230000001815 facial effect Effects 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- FZWBNHMXJMCXLU-BLAUPYHCSA-N isomaltotriose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)O1 FZWBNHMXJMCXLU-BLAUPYHCSA-N 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000003607 modifier Substances 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000019612 pigmentation Effects 0.000 description 1
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 239000001818 polyoxyethylene sorbitan monostearate Substances 0.000 description 1
- 235000010989 polyoxyethylene sorbitan monostearate Nutrition 0.000 description 1
- 229940113124 polysorbate 60 Drugs 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 229940068968 polysorbate 80 Drugs 0.000 description 1
- 239000001508 potassium citrate Substances 0.000 description 1
- 229960002635 potassium citrate Drugs 0.000 description 1
- QEEAPRPFLLJWCF-UHFFFAOYSA-K potassium citrate (anhydrous) Chemical compound [K+].[K+].[K+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O QEEAPRPFLLJWCF-UHFFFAOYSA-K 0.000 description 1
- 235000011082 potassium citrates Nutrition 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 239000003223 protective agent Substances 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 239000013074 reference sample Substances 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L29/00—Foods or foodstuffs containing additives; Preparation or treatment thereof
- A23L29/015—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L29/00—Foods or foodstuffs containing additives; Preparation or treatment thereof
- A23L29/03—Organic compounds
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L29/00—Foods or foodstuffs containing additives; Preparation or treatment thereof
- A23L29/10—Foods or foodstuffs containing additives; Preparation or treatment thereof containing emulsifiers
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L29/00—Foods or foodstuffs containing additives; Preparation or treatment thereof
- A23L29/30—Foods or foodstuffs containing additives; Preparation or treatment thereof containing carbohydrate syrups; containing sugars; containing sugar alcohols, e.g. xylitol; containing starch hydrolysates, e.g. dextrin
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/18—Peptides; Protein hydrolysates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/08—Anti-ageing preparations
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/20—Chemical, physico-chemical or functional or structural properties of the composition as a whole
- A61K2800/30—Characterized by the absence of a particular group of ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
- A61K2800/59—Mixtures
- A61K2800/592—Mixtures of compounds complementing their respective functions
- A61K2800/5922—At least two compounds being classified in the same subclass of A61K8/18
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/80—Process related aspects concerning the preparation of the cosmetic composition or the storage or application thereof
- A61K2800/84—Products or compounds obtained by lyophilisation, freeze-drying
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Polymers & Plastics (AREA)
- Nutrition Science (AREA)
- Engineering & Computer Science (AREA)
- Food Science & Technology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Mycology (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Dermatology (AREA)
- Gerontology & Geriatric Medicine (AREA)
- Inorganic Chemistry (AREA)
- Birds (AREA)
- Epidemiology (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
The invention relates to the technical field of cosmetics, and particularly relates to an anti-aging composition, freeze-dried powder containing the anti-aging composition and a preparation method of the freeze-dried powder. The anti-aging composition consists of 0.2 to 2 parts by weight of serum albumin and 0.05 to 40 parts by weight of oligopeptides. The serum albumin and the specific oligopeptide are compounded, and test results show that the compounded composition has remarkable moisturizing and anti-aging effects. The freeze-dried powder prepared by the composition has obvious anti-aging effect, the frozen appearance is beautiful and smooth, no crack, no atrophy, no wall separation, no roughness, no delamination and long storage life; meanwhile, no preservative is added, so that the safety is higher.
Description
Technical Field
The invention relates to the technical field of cosmetics, in particular to an anti-aging composition, freeze-dried powder containing the anti-aging composition and a preparation method of the freeze-dried powder.
Background
"anti-aging" is never a stale topic. The largest organ on the surface of the human body is, by no means, the skin, which is in direct contact with the external environment, and is subjected to conditions such as: air pollution, oxidation, ultraviolet irradiation, and other harmful factors. People who love beauty will not feel worry all the time. Furthermore, with age, the skin is more or less characterised by facial ageing, such as wrinkles, decreased elasticity, pigmentation and the like. This phenomenon is contrary to the current pursuit of beauty.
Although the eight five-flower efficacy declaration appears in the market in the past rapid development stage, the anti-aging effect is still high, and the development quantity of the anti-aging effect product in the markets in China and Japan is rapidly increased according to the development trend of new products in the world, which is in line with the demand of consumers.
However, most of the anti-aging products on the market are added with concepts, and the number of products really effective is very small. At the same time, consumers are still at the level of the loss of cognition, only knowing the "alleged ingredient" and not knowing the exertion of a specific role. This has led to a very popular "fry concept" for some time, ignoring the real value of the product itself.
The majority of the products currently on the market are traditional cosmetic formulations such as: the water emulsion cream, and the products of the preparation formulation can not protect the activity of the functional raw materials in the formula, thereby greatly reducing the efficacy of the product. In particular, the development of a composition with remarkable anti-aging effect and a freeze-dried powder preparation capable of protecting the activity of functional raw materials of the product for a long time have important practical significance.
Disclosure of Invention
In view of the above, the present invention aims to provide an anti-aging composition, a lyophilized powder containing the anti-aging composition, and a preparation method thereof. The composition provided by the invention has a remarkable anti-aging effect, and the freeze-dried powder prepared from the composition has a good anti-aging effect, is beautiful and smooth in frozen appearance, is free from crack, atrophy, wall separation, roughness and delamination, and is long in storage life; meanwhile, no preservative is added, so that the safety is higher.
In order to realize the purpose of the invention, the invention adopts the following technical scheme:
the invention provides an anti-aging composition, which consists of 0.2 to 2 parts of serum albumin and 0.05 to 40 parts of oligopeptides in parts by weight.
In some embodiments, the anti-aging composition consists of 0.2 to 1 part serum albumin and 0.4 to 1.5 parts oligopeptides.
In some embodiments, the oligopeptide is at least one of oligopeptide-1, oligopeptide-3, oligopeptide-5.
The invention also provides application of the composition in preparing health care products and/or cosmetics with anti-aging effect.
The invention also provides anti-aging freeze-dried powder which consists of the anti-aging composition, a stabilizer and deionized water.
In some embodiments, the lyophilized powder is made from the following components in parts by weight:
0.2 to 1 portion of serum albumin, 0.4 to 1.5 portions of oligopeptide, 207 to 257.23 portions of stabilizer and 771.37 to 821 portions of deionized water.
In some embodiments, the stabilizing agent is one or more of a lyoprotectant, an acid-base modifier, an emulsifier.
Wherein the freeze-drying protective agent is one or more of trehalose, glycine, mannitol, dextran and lactose;
the acid-base regulator is one or more of disodium hydrogen phosphate, sodium dihydrogen phosphate, amino acid and potassium citrate.
The emulsifier is one or more of polysorbate-20, polysorbate-60 and polysorbate-80.
In some embodiments, the lyophilized powder is made from the following components:
1 part of serum albumin, 1 part of oligopeptide-5, 2 parts of trehalose, 205 parts of mannitol and 821 parts of deionized water.
In some embodiments, the lyophilized powder is made from the following components:
1 part of serum albumin, 1.5 parts of oligopeptides, 250 parts of stabilizing agent and 8978 parts of deionized water zxft 8978;
wherein, the oligopeptides are: oligopeptide-1.5 parts, oligopeptide-3.5 parts and oligopeptide-5.5 parts;
the stabilizer is: 10 parts of trehalose and 240 parts of mannitol.
In some embodiments, the lyophilized powder is made from the following components:
1 part of serum albumin, 0.4 part of oligopeptides, 257.23 parts of stabilizer and 771.37 parts of deionized water;
wherein, the oligopeptides comprise oligopeptide-1.2 parts and oligopeptide-5.2 parts;
the stabilizer is: trehalose 0.7 parts, glycine 1 part, sodium dihydrogen phosphate 0.06 parts, disodium hydrogen phosphate 0.4 parts, polysorbate-20.07 parts and mannitol 255 parts.
The invention also provides a preparation method of the anti-aging freeze-dried powder, which comprises the steps of mixing the serum albumin, the oligopeptides, the stabilizer and the deionized water, filtering for sterilization, and carrying out vacuum freeze-drying to obtain the anti-aging freeze-dried powder.
In some embodiments, the filter sterilization is performed by sequentially passing through 0.45 μm and 0.22 μm filter elements.
In some embodiments, the vacuum freeze-drying is performed by pre-freezing at-40 ℃ for 1-4 h, vacuumizing to 0.19mbar, and heating for sublimation drying for 20-28 h until the water is completely sublimated.
In some embodiments, the preparation method of the anti-aging freeze-dried powder comprises the following steps:
dissolving and mixing raw materials of the freeze-dried powder in sequence, filtering through filter elements with the particle size of 0.45 mu m and 0.22 mu m respectively, adding the mixture into a container in a hundred-grade area, placing the container in a vacuum freeze-drying machine after plugging, pre-freezing for 1 to 4 hours at the temperature of minus 40 ℃, vacuumizing to 0.19mbar, heating for sublimation and drying for 20 to 28 hours until the water is completely sublimated, and sealing by pressing a plug under the vacuum condition and then bundling and packaging.
The serum albumin and the specific oligopeptide are compounded, and test results show that the compounded composition has remarkable moisturizing and anti-aging effects. The freeze-dried powder prepared by the composition has obvious anti-aging effect and long storage life; meanwhile, no preservative is added, so that the safety is higher.
Drawings
In order to more clearly illustrate the embodiments of the present invention or the technical solutions in the prior art, the drawings used in the description of the embodiments or the prior art will be briefly described below.
FIG. 1 shows the recovery effect of three oligopeptides on cell scratch;
FIG. 2 is a graph of the mean values of examples 1-3 after testing and comparative examples 1-8 after testing, respectively, showing the effect of lyophilized powder on skin moisture content;
FIG. 3 is a graph of skin wrinkles, wherein 3-a is a result of the fourth week after using the lyophilized powder of comparative example 5, the overrun inclusion ratio in the whole data system is 53%;3-b is the result of the fourth week after using the lyophilized powder of example 3, the overrun occupancy ratio in the whole data system is 89%;
FIG. 4 is a skin texture condition, where 4-a is the result of the fourth week after use of the lyophilized powder of comparative example 5, with an over-inclusion ratio of 16% in the entire data system; 4-b is the results of the fourth week after using the lyophilized powder of example 3, with an over-range of 93% in the overall data system (the test instrument is VISIA, with a certain amount of its own database inside, 16% indicating that the degree of good texture state is only over 16% of the skin texture state of the person in the database, and 93% indicating that the degree of good texture state is over 93% of the skin texture state of the person in the database).
Detailed Description
The invention discloses an anti-aging composition, freeze-dried powder containing the anti-aging composition and a preparation method thereof, and a person skilled in the art can realize the anti-aging composition by appropriately improving process parameters by referring to the content. It is expressly intended that all such similar substitutes and modifications which would be obvious to one skilled in the art are deemed to be included in the invention. While the methods and applications of this invention have been described in terms of preferred embodiments, it will be apparent to those of ordinary skill in the art that variations and modifications in the methods and applications described herein, as well as other suitable variations and combinations, may be made to implement and use the techniques of this invention without departing from the spirit and scope of the invention.
The description of the disclosed embodiments is provided to enable any person skilled in the art to make or use the present invention. Various modifications to these embodiments will be readily apparent to those skilled in the art, and the generic principles defined herein may be applied to other embodiments without departing from the spirit or scope of the invention. Thus, the present invention is not intended to be limited to the embodiments shown herein but is to be accorded the widest scope consistent with the principles and novel features disclosed herein.
The test materials adopted by the invention are all common commercial products and can be purchased in the market.
Interpretation of terms:
freeze-drying powder: freezing the water in the components in advance by adopting a vacuum freeze-drying method of a freeze dryer, and then sublimating the frozen water in the components in a vacuum sterile environment to obtain a freeze-dried product.
The invention is further illustrated by the following examples:
example 1 preparation of anti-aging lyophilized powder of the invention
Weighing 1 part of serum albumin, 1 part of oligopeptide (oligopeptide-5), 207 parts of stabilizer (trehalose 2 and mannitol 205) and 821 parts of deionized water, uniformly mixing, filtering and sterilizing, placing in a penicillin bottle of 3ml/5ml, plugging, placing in a vacuum freeze dryer, pre-freezing for 1-4 h at-40 ℃, vacuumizing to 0.19mbar, heating for sublimation drying for 20-28 h until water is completely sublimated, capping and packaging after plugging and sealing, thus obtaining the anti-aging freeze-dried powder.
Example 2 preparation of anti-aging lyophilized powder of the present invention
Weighing 1 part of serum albumin, 1.5 parts of oligopeptides, 250 parts of stabilizer and 8978 parts of deionized water of 777.5, mixing uniformly, filtering and sterilizing, putting the mixture into a penicillin bottle of 3ml/5ml, placing the penicillin bottle into a vacuum freeze dryer after plugging, pre-freezing for 1-4 h at minus 40 ℃, vacuumizing to 0.19mbar, heating for sublimation and drying for 20-28 h until water is completely sublimated, and capping and packaging after plugging and sealing to obtain the anti-aging freeze-dried powder.
Wherein, the oligopeptides are: oligopeptide-1.5 parts, oligopeptide-3.5 parts and oligopeptide-5.5 parts.
Wherein, the stabilizer is: 10 parts of trehalose and 240 parts of mannitol.
Example 3 preparation of anti-aging lyophilized powder of the invention
Weighing 1 part of serum albumin, 0.4 part of oligopeptides, 257.23 parts of stabilizer and 771.37 parts of deionized water, uniformly mixing, filtering and sterilizing, putting into a penicillin bottle of 3ml/5ml, adding a stopper, putting into a vacuum freeze dryer, adding the stopper, putting into the vacuum freeze dryer, pre-freezing for 1-4 h at-40 ℃, vacuumizing to 0.19mbar, heating for sublimation and drying for 20-28 h until water is completely sublimated, pressing the stopper, sealing, and then bundling and packaging to obtain the anti-aging freeze-dried powder.
Wherein, the oligopeptides comprise oligopeptide-1.2 parts and oligopeptide-5.2 parts;
the stabilizer is: trehalose 0.7 parts, glycine 1 part, sodium dihydrogen phosphate 0.06 parts, disodium hydrogen phosphate 0.4 parts, polysorbate-20.07 parts and mannitol 255 parts.
Comparative example 1
Comparative example 1 is different from example 1 in that serum albumin was not added while 45 parts of mannitol was reduced, and the remaining components and amounts were the same as in example 1.
Comprises the following components: oligopeptide-5 parts, stabilizer 162 parts (trehalose 2 parts, mannitol 160 parts), deionized water 867 parts
The lyophilized powder was prepared in the same manner as in example 1.
Comparative example 2 preparation of lyophilized powder
Comparative example 2 differs from example 1 in that no oligopeptides were added and the stabilizer consisted of 10 parts trehalose and 195 parts mannitol.
Comprises the following components: 1 part of serum albumin, 205 parts of stabilizer (10 parts of trehalose and 195 parts of mannitol) and 824 parts of deionized water.
The process for preparing the lyophilized powder is the same as in example 1.
Comparative example 3 preparation of lyophilized powder
Comparative example 3 is different from example 2 in that trehalose was reduced by 5 parts and mannitol was reduced by 80 parts without adding serum albumin, and the remaining components and amounts were the same as in example 2.
Comprises the following components: 1.5 parts of oligopeptides, 165 parts of stabilizer and 8978 parts of deionized water of 863.5 parts;
wherein, the oligopeptides are: oligopeptide-10.5 parts, oligopeptide-30.5 parts and oligopeptide-50.5 parts; the stabilizer is: 5 parts of trehalose and 160 parts of mannitol.
The process for preparing the lyophilized powder is the same as in example 2.
Comparative example 4 preparation of lyophilized powder
Comparative example 4 differs from example 2 in that, without addition of oligopeptides, trehalose was reduced by 5 parts while mannitol was reduced by 80 parts, and the remaining components and relative contents were the same as in example 2.
Comprises the following components: 1 part of serum albumin, 165 parts of a stabilizer and 864 parts of deionized water;
wherein, the stabilizer is: 5 parts of trehalose and 160 parts of mannitol.
The process for preparing the lyophilized powder is the same as in example 2.
Comparative example 5 preparation of lyophilized powder
Comparative example 5 is different from example 3 in that mannitol was reduced by 100 parts without adding sodium dihydrogen phosphate and without adding disodium hydrogen phosphate, and the remaining components and amounts were the same as example 3.
Comprises the following components: 1 part of serum albumin, 0.4 part of oligopeptides, 5363 parts of stabilizer 156.77 parts, 3242 parts of deionized water 871.83 parts,
wherein, the oligopeptides are: oligopeptide-10.2 parts, oligopeptide-50.2 parts;
the stabilizer is: trehalose 0.7 parts, glycine 1 part, polysorbate-20.07 parts and mannitol 155 parts.
The process for preparing the lyophilized powder is the same as in example 3.
Comparative example 6 preparation of lyophilized powder
Comparative example 6 is different from example 3 in that mannitol was reduced by 100 parts without adding serum albumin, sodium dihydrogen phosphate and disodium hydrogen phosphate, and the remaining components and amounts thereof were the same as in example 2.
Comprises the following components: 0.4 parts of oligopeptides, 5363 parts of stabilizer 156.77 parts and 3242 parts of deionized water 872.83 parts;
wherein, the oligopeptides are: oligopeptide-1, oligopeptide-5, oligopeptide-10.2 parts, oligopeptide-50.2 parts;
the stabilizer is: trehalose 0.7 parts, glycine 1 part, polysorbate-20.07 parts and mannitol 155 parts.
The process for preparing the lyophilized powder is the same as in example 3.
Comparative example 7 preparation of lyophilized powder
Comparative example 7 is different from example 3 in that mannitol was reduced by 100 parts without adding serum albumin, polysorbate-20, sodium dihydrogen phosphate and disodium hydrogen phosphate, and the remaining components and relative contents were the same as those of example 2.
Comprises the following components: 0.4 part of oligopeptides, 156.7 parts of stabilizing agent and 8978 parts of deionized water 872.9 parts;
wherein, the oligopeptides are: oligopeptide-1, oligopeptide-5, oligopeptide-10.2 parts, oligopeptide-50.2 parts;
the stabilizer is: 0.7 part of trehalose, 1 part of glycine and 155 parts of mannitol.
The process for preparing the lyophilized powder is the same as in example 3.
Comparative example 8 preparation of lyophilized powder
Comparative example 8 is different from example 3 in that, without adding oligopeptides, polysorbate-20, sodium dihydrogen phosphate and disodium hydrogen phosphate, mannitol was reduced by 100 parts, and the remaining components and relative contents were the same as those of example 2.
Comprises the following components: 1 part of serum albumin, 156.7 parts of stabilizing agent and 5363 parts of deionized water 872.3;
wherein, the stabilizer is: 0.7 part of trehalose, 1 part of glycine and 155 parts of mannitol.
The process for preparing the lyophilized powder is the same as in example 3.
Example 4 testing of appearance of lyophilized powder
TABLE 1
As can be seen from table 1, the freeze-dried powders of embodiments 1 to 3 of the present invention have good appearance, which is specifically represented as: the surface is not rough, and the conditions of layering, atrophy, cracking and wall separation do not exist, while the appearance state of the freeze-dried powder prepared by adopting other formulas in comparative examples 1-8 is poorer.
Example 5 oligopeptide cell regeneration repair assay
Experimental products: oligopeptide-1, oligopeptide-3, oligopeptide-5
The effect of oligopeptide-1, oligopeptide-3 and oligopeptide-5 on repairing and proliferating the scratched cells is measured by using a cell culture technology, and the test method comprises the following steps: firstly culturing cells, then putting a mark pen at the back of a 6-hole plate, using a ruler to draw transverse lines uniformly, and traversing through holes approximately every 0.5-1 cm. Each hole passes through at least 5 lines.
Resuspending the cells in a cell passaging step at a density of about 25000 to 30000 cells/mL and in an amount slightly greater than that required for plating. When plating, the cell suspension was added to a 6-well plate using a pipette gun while shaking the cell suspension, and 2ml of the cell suspension was added to each well. And after the plate paving is finished, putting the 6-hole plate into a cell culture box, and culturing for 24 +/-2 hours.
The gun head is perpendicular to the transverse line scratch on the back as much as possible compared with the straight ruler, and the gun head is perpendicular and cannot be inclined. The cells were washed 3 times with PBS, the scraped cells were washed off, 2ml of maintenance serum medium containing drug was added at 1 concentration per well, and 2ml of complete medium containing no drug was added to the negative control group. The cells were cultured in a 37-degree-5-vol CO2 incubator. Samples were taken at 0, 24 hours and photographed. The results are shown in FIG. 1.
As can be seen from FIG. 1, the scratches of the cells recover to different degrees from 0h to 24h, which indicates that the oligopeptides oligopeptide-1, oligopeptide-3 and oligopeptide-5 have good effects of promoting cell proliferation and repair and have good anti-aging effects.
Example 6 testing of moisturizing and anti-aging efficacy of lyophilized powder
A good anti-aging product needs to be established on the basis of a good moisturizing effect, and the moisturizing effect of the freeze-dried powders in the examples 1-3 and the comparative examples 1-8 is compared by using an in-vivo test in the embodiment.
Experimental products: EXAMPLES 1-3 AND COMPARATIVE EXAMPLES 1-8 Freeze-dried powder + physiological saline
Blank control: physiological saline
The test method comprises the following steps: 35 volunteers meeting the requirements are selected, and each volunteer is used in the morning and evening, a half-face experimental article and a half-face blank control article, and skin moisture values are tested in the Ceilala Stem cell company at the 0 th week, the 1 st week, the 2 nd week, the 3 rd week and the 4 th week, and the results are shown in a graph 2 and a table 2.
Testing an instrument: skin moisture tester (Corneometer CM825 MDD).
TABLE 2 skin moisture values
As can be seen from Table 1 and FIG. 2, the compositions of the present invention have scientific mixture ratio, the moisture value (mean moisture value in the fourth week of examples 1 to 3) is increased by 32.29% compared with that before use (mean moisture value before use in examples 1 to 3) at week 4, and compared with comparative examples 1 to 8, the compositions show significant difference (p < 0.05) in improving skin moisture, which indicates that the composition of the present invention has significant synergistic effect.
Example 7 Freeze-dried powder anti-aging efficacy test
The anti-wrinkle effect of the lyophilized powders of examples 1-3 and comparative examples 1-8 on skin was evaluated using the VISIA skin imaging system. This example illustrates the study of example 3 and comparative example 5
Experimental products: 3+ physiological saline solution
Comparison products: comparative example 5 lyophilized powder + physiological saline
The test method comprises the following steps: and selecting 35 volunteers meeting the requirements, using the experimental sample for half face and the blank reference sample for half face every morning and evening, and testing the skin in the Ceilera stem cell company in 4 th week, wherein the results are shown in figures 3-4.
Testing the instrument: skin test system (VISIA).
As can be seen from FIGS. 3 to 4, the freeze-dried powder of the invention has good wrinkle-removing effect, can well smooth the texture, and has an effect obviously superior to that of the freeze-dried powder of the comparative example.
The freeze-dried powder of the embodiment 3 with the preservation time of 1 year is adopted to carry out the tests of the embodiments 6 to 7, and the results are similar to those of the embodiments 6 to 7 and have no obvious difference. The freeze-dried powder still has obvious anti-aging effect after being stored for a long time.
The foregoing is only a preferred embodiment of the present invention, and it should be noted that, for those skilled in the art, various modifications and decorations can be made without departing from the principle of the present invention, and these modifications and decorations should also be regarded as the protection scope of the present invention.
Claims (3)
1. An anti-aging freeze-dried powder is characterized by consisting of 1 part of serum albumin, 0.2 part of oligopeptide, 0.7 part of trehalose, 1 part of glycine, 0.06 part of sodium dihydrogen phosphate, 0.4 part of disodium hydrogen phosphate, 0.07 part of polysorbate-20 and 255 parts of mannitol.
2. The preparation method of the anti-aging freeze-dried powder of claim 1, wherein the anti-aging freeze-dried powder is obtained by mixing serum albumin, oligopeptides, a stabilizer and deionized water, filtering for sterilization, and performing vacuum freeze-drying.
3. The preparation method according to claim 2, wherein the vacuum freeze-drying is performed by pre-freezing at-40 ℃ for 1-4 h, vacuumizing to 0.19mbar, and heating for sublimation drying for 20-28 h until water is completely sublimated.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910837576.6A CN110613628B (en) | 2019-09-05 | 2019-09-05 | Anti-aging composition, freeze-dried powder containing anti-aging composition and preparation method of freeze-dried powder |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910837576.6A CN110613628B (en) | 2019-09-05 | 2019-09-05 | Anti-aging composition, freeze-dried powder containing anti-aging composition and preparation method of freeze-dried powder |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN110613628A CN110613628A (en) | 2019-12-27 |
| CN110613628B true CN110613628B (en) | 2022-11-01 |
Family
ID=68922579
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201910837576.6A Active CN110613628B (en) | 2019-09-05 | 2019-09-05 | Anti-aging composition, freeze-dried powder containing anti-aging composition and preparation method of freeze-dried powder |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN110613628B (en) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111067873A (en) * | 2020-03-06 | 2020-04-28 | 广州市赛迪药业科技有限公司 | Production process of serum protein freeze-dried powder |
| CN113499279B (en) * | 2021-06-17 | 2023-10-20 | 广东鸿懿化妆品有限公司 | Whitening, repairing and anti-aging freeze-dried small milk tablet and preparation process thereof |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105456050A (en) * | 2015-12-31 | 2016-04-06 | 青岛美博生物技术有限公司 | Freeze-dried powder, essence and skincare set for repairing acne marks and scars |
| CN108403469A (en) * | 2018-05-29 | 2018-08-17 | 北京原肽干细胞医学研究院有限公司 | A kind of composition, preparation method and its purposes in cosmetics |
-
2019
- 2019-09-05 CN CN201910837576.6A patent/CN110613628B/en active Active
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105456050A (en) * | 2015-12-31 | 2016-04-06 | 青岛美博生物技术有限公司 | Freeze-dried powder, essence and skincare set for repairing acne marks and scars |
| CN108403469A (en) * | 2018-05-29 | 2018-08-17 | 北京原肽干细胞医学研究院有限公司 | A kind of composition, preparation method and its purposes in cosmetics |
Also Published As
| Publication number | Publication date |
|---|---|
| CN110613628A (en) | 2019-12-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN105748400B (en) | A kind of yeast polypeptides freeze-dried powder mask composition and preparation method thereof | |
| CN110613628B (en) | Anti-aging composition, freeze-dried powder containing anti-aging composition and preparation method of freeze-dried powder | |
| CN105055261B (en) | A kind of antipollution skin-protection product and preparation method thereof | |
| EP3369412B1 (en) | Method for producing pressed make-up powder | |
| CN104997652A (en) | Crease resistance and moisture retention liposome, and preparation method and application thereof | |
| KR101895038B1 (en) | Dissolvable film comprising spicule and use thereof | |
| EP3159044B1 (en) | Long-lasting powder essence composition with improved coloring and skin feeling and preparation method thereof | |
| CN107372464B (en) | Transportation preservation solution for maintaining activity of mesenchymal stem cells and preparation method thereof | |
| Chang et al. | Role of fatty acid composites in the toxicity of titanium dioxide nanoparticles used in cosmetic products | |
| WO2021077812A1 (en) | Umbilical cord mesenchymal stem cell factor freeze-dried powder, preparation method therefor and application thereof | |
| CN104721097A (en) | Cosmetic composition with functions of whitening, aging resisting, wrinkle removing and freckle removing and cosmetics with cosmetic composition | |
| CN106880505B (en) | Antioxidant nanometer ethosome rose essence and preparation method thereof | |
| CN105640819A (en) | Skin tendering smoothening whitening exfoliating microsphere and application thereof | |
| CN106109391A (en) | A kind of potent moisture retention water and preparation method thereof | |
| CN109303761A (en) | A kind of load has chitosan microball composition of the Stem Cell Activity factor and its preparation method and application | |
| CN108888527B (en) | Freeze-dried powder for improving skin dryness and sensitivity and preparation method thereof | |
| CN107929113A (en) | Antipollution skin care compositions and cosmetics | |
| WO2012026346A1 (en) | Cytoprotective agent | |
| CN105073089B (en) | Cosmetic use of Q-base | |
| CN110897991A (en) | Lip gloss with skin care function and preparation method thereof | |
| CN113499279B (en) | Whitening, repairing and anti-aging freeze-dried small milk tablet and preparation process thereof | |
| CN111281828B (en) | Edible attapulgite based lipstick and preparation method thereof | |
| CN113797101A (en) | Substrate film, composite film containing astaxanthin and high-molecular polysaccharide, preparation method and application | |
| CN111135137B (en) | Periplaneta americana freeze-dried powder and preparation method and application thereof | |
| CN110227058A (en) | Pleiotrophic factor composition and its preparation method and application |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |